WealthStone’s Antares Pharma, Inc. ATRS Stock Holding History

WealthStone’s Portfolio ATRS Stock Details ATRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-249	Closed	-$819	–	653
2019 Q2	$819	Buy	+249	New	+$720	﹤0.01%	716

Other funds holding ATRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

MWP

MYCIO Wealth Partners Philadelphia, Pennsylvania $502M AUM 11.65% 1-Year Est. Return

WealthStone's ATRS Position: Q3 2019 in Review

WealthStone sold out of Antares Pharma, Inc. (ATRS) in Q3 2019, closing a stake of 249 shares — an estimated $819 sold.

WealthStone first reported a position in ATRS in Q2 2019 and held it in 1 quarter. The position peaked at $819 in Q2 2019. 135 funds tracked by Wall St. Rank hold ATRS as of Q3 2019.

WealthStone reported no remaining Antares Pharma, Inc. position as of Q3 2019 after selling out during the quarter.
WealthStone sold 249 Antares Pharma, Inc. shares in Q3 2019, an estimated $819.
WealthStone first reported a position in Antares Pharma, Inc. in Q2 2019 and held it in 1 quarter.
WealthStone's Antares Pharma, Inc. position peaked at $819 in Q2 2019.
135 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q3 2019.

Based on WealthStone's 13F filing for Q3 2019, filed 15 Nov 2019.